Streamlining Medicare Infusion Therapy Prior Authorization

Managing Medicare Infusion Therapy prior authorization requires precise navigation of federal and local policies. Klivira automates the submission process, ensuring compliance with payer-specific requirements for these critical services.

Infusion therapy, encompassing in-office, outpatient, or home administration of specialty drugs, presents unique prior authorization challenges under Medicare. Revenue cycle directors and prior authorization coordinators must contend with specific coverage determinations and site-of-service requirements to prevent denials and ensure timely patient care. Understanding the nuances of Medicare's PA landscape for infusion services is paramount for operational efficiency.

Navigating Medicare Prior Authorization for Infusion Therapy

Traditional Medicare (Parts A and B) has a limited scope for prior authorization compared to Medicare Advantage plans. For infusion therapy, where PA is required, submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira's MAC-aware routing ensures that prior authorization requests for procedures typically coded with CPTs such as 96360-96379 (intravenous infusion) and associated HCPCS J-codes are directed to the correct entity, such as Noridian, NGS, WPS, Palmetto, FCSO, or Novitas.

Medical Necessity Criteria and Site-of-Service Requirements

Medicare's medical necessity for infusion therapy is primarily governed by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by the MACs. A critical dimension for infusion therapy is the site-of-service review, which determines if home, outpatient hospital (HOPD), or office-based infusion is appropriate. Documentation must robustly support the chosen site based on clinical necessity, patient stability, and safety protocols outlined in the relevant NCD or LCD.

Common Denial Reasons and Appeals for Infusion Therapy

Denials for Medicare Infusion Therapy prior authorization often stem from insufficient documentation of medical necessity, lack of compliance with site-of-service criteria, or failure to meet prior-conservative-treatment requirements. In some cases, the prescribed drug may not be covered under Medicare Part B (medical benefit) and may fall under Part D (pharmacy benefit), necessitating a different PA pathway. While Traditional Medicare has a more defined appeals process than commercial payers, understanding the specific NCD/LCD citations and presenting comprehensive clinical evidence is key to successful reconsideration.

Klivira's Approach to Medicare Infusion Therapy PA

Klivira streamlines the prior authorization process for infusion therapy by integrating directly with EMRs and connecting with MAC submission channels. Our platform incorporates NCD/LCD-aware policy logic to guide documentation and submission, reducing manual effort and improving first-pass authorization rates. While the applicability of CMS-0057-F is primarily for Medicare Advantage and other managed care plans, Klivira ensures that all relevant Traditional Medicare PA requirements are met where applicable.

Considerations for Medicare Part D Infusion Drugs

For infusion drugs covered under Medicare Part D, prior authorization is administered by the private Part D plans according to their CMS-approved formularies and step-therapy protocols. Klivira supports the electronic prior authorization (ePA) process for Part D drugs, facilitating submissions to Pharmacy Benefit Managers (PBMs) and ensuring adherence to NCPDP SCRIPT standards where applicable. This dual capability addresses the varied PA requirements for infusion therapies across Medicare benefits.

Frequently asked questions

What is the primary difference in prior authorization for infusion therapy between Original Medicare and Medicare Advantage?

Original Medicare (Parts A and B) has a limited scope for prior authorization, primarily through MACs for specific services and programs. Medicare Advantage plans, run by private insurers, typically have broader PA requirements and utilize their own medical policies similar to commercial payers. Klivira adapts its workflows for both, routing through MACs for Original Medicare and directly to MA plans.

How does Klivira handle site-of-service review for Medicare Infusion Therapy?

Klivira's platform is configured with NCD and LCD logic, which often includes specific criteria for site-of-service (e.g., home, outpatient hospital, office). We guide providers in submitting the necessary documentation to support the chosen site, aligning with Medicare's requirements and reducing the likelihood of denials related to inappropriate service location.

Which entities handle prior authorizations for Original Medicare Infusion Therapy?

For Original Medicare, prior authorizations for infusion therapy (where required) are handled by the Medicare Administrative Contractors (MACs) specific to the provider's jurisdiction. Examples include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. Klivira automates the routing of these requests to the appropriate MAC.

Are there specific NCDs or LCDs for infusion therapy that Klivira references?

Yes, Klivira incorporates relevant National Coverage Determinations (NCDs) from CMS and Local Coverage Determinations (LCDs) published by the MACs. These policies outline the medical necessity criteria, indications, and sometimes site-of-service requirements for various infusion therapies. Our system uses this policy intelligence to support accurate PA submissions without inventing specific policy IDs.

Does Klivira assist with prior authorization for infusion drugs covered under Medicare Part D?

Yes, Klivira supports prior authorization for infusion drugs covered under Medicare Part D. These requests are typically processed as electronic prior authorizations (ePA) through commercial Part D plans and their PBMs, following NCPDP SCRIPT standards. Klivira streamlines these submissions, ensuring compliance with Part D plan formularies and step-therapy protocols.